1,7-Di(propan-2-yl)-3,4-dihydroquinolin-2-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 1,7-Di(propan-2-yl)-3,4-dihydroquinolin-2-one
• 英文别名: 1,7-di(propan-2-yl)-3,4-dihydroquinolin-2-one
• 化学式: C₁₅H₂₁NO
• 分子量: 231.33
• InChiKey: QQOQXCSBSQEXLW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• N-SULFONYLATED TETRAHYDROQUINOLINES AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
  申请人：Glick Gary D.

  公开号：US20140088094A1

  公开（公告）日：2014-03-27

  The invention provides tetrahydroquinoline and related compounds, pharmaceutical compositions, methods of inhibiting RORγ activity, reducing the amount of IL-17 in a subject, and treating immune disorders and inflammatory disorders using such tetrahydroquinoline and related compounds are provided.

  本发明提供四氢喹啉及相关化合物、制药组合物、抑制RORγ活性的方法、减少受试者体内IL-17的数量以及使用该四氢喹啉及相关化合物治疗免疫性疾病和炎症性疾病的方法。
• NOVEL BICYCLIC BROMODOMAIN INHIBITORS
  申请人：ZENITH EPIGENETICS CORP.

  公开号：US20160159801A1

  公开（公告）日：2016-06-09

  The invention relates to substituted bicyclic compounds, which are useful for inhibition of BET protein function by binding to bromodomains, pharmaceutical compositions comprising these compounds, and use of the compounds and compositions in therapy.

  该发明涉及用于通过结合溴域抑制BET蛋白功能的取代双环化合物，包括这些化合物的制药组合物以及在治疗中使用这些化合物和组合物。
• Bicyclic bromodomain inhibitors
  申请人：ZENITH EPIGENETICS LTD.

  公开号：US10010556B2

  公开（公告）日：2018-07-03

  The invention relates to substituted bicyclic compounds, which are useful for inhibition of BET protein function by binding to bromodomains, pharmaceutical compositions comprising these compounds, and use of the compounds and compositions in therapy.

  本发明涉及取代的双环化合物，这些化合物可通过与溴结构域结合来抑制 BET 蛋白的功能；本发明还涉及包含这些化合物的药物组合物，以及这些化合物和组合物在治疗中的应用。
• Lysyl oxidase-like 2 inhibitors and uses thereof
  申请人：PharmAkea, Inc.

  公开号：US10766860B2

  公开（公告）日：2020-09-08

  Described herein are compounds that are LOXL2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with LOXL2 activity.

  本文描述了作为 LOXL2 抑制剂的化合物、制造此类化合物的方法、包含此类化合物的药物组合物和药物，以及使用此类化合物治疗与 LOXL2 活性相关的病症、疾病或失调的方法。
• Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof
  申请人：PharmAkea, Inc.

  公开号：US11072585B2

  公开（公告）日：2021-07-27

  Described herein are compounds that are LOXL2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with LOXL2 activity.

  本文描述了作为 LOXL2 抑制剂的化合物、制造此类化合物的方法、包含此类化合物的药物组合物和药物，以及使用此类化合物治疗与 LOXL2 活性相关的病症、疾病或失调的方法。